Literature DB >> 19952276

Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.

Catherine A Brownstein1, Junhui Zhang, Althea Stillman, Bruce Ellis, Nancy Troiano, Douglas J Adams, Caren M Gundberg, Richard P Lifton, Thomas O Carpenter.   

Abstract

Inactivating mutations of PHEX cause X-linked hypophosphatemia and result in increased circulating fibroblast growth factor 23 (FGF23). FGF23 action is dependent upon Klotho, which converts FGF receptor 1 into an FGF23-specific receptor. Disruption of Klotho results in a complex bone phenotype and hyperphosphatemia, the converse phenotype of X-linked hypophosphatemia. We examined effects of disrupting both Klotho and PHEX by creating a double-knockout (Klotho/HYP) mouse. The combined disruption corrected the hypophosphatemia in HYP mice, indicating that Klotho is epistatic to PHEX. FGF23 levels remained elevated in all groups except wild-type, indicating that Klotho is necessary for FGF23-dependent phosphaturic activity. 1,25-Dihydroxyvitamin D levels, reduced in HYP mice, were comparably elevated in Klotho and Klotho/HYP mice, demonstrating that Klotho is necessary for FGF23's effect on vitamin D metabolism. Serum PTH levels were reduced in both Klotho and Klotho/HYP mice. Moreover, the Klotho null phenotype persisted in Klotho/HYP, maintaining the runty phenotype and decreased life span of Klotho null mice. Notably, microcomputed tomography analysis demonstrated greater trabecular bone volume fraction in Klotho/HYP mice than that in all other groups (Klotho/HYP, 56.2 +/- 6.3%; Klotho, 32.5 +/- 10.3%; HYP, 8.6 +/- 7.7%; and wild type, 21.4 +/- 3.4%; P < 0.004). Histomorphometric analysis confirmed the markedly increased trabecular bone density in Klotho/HYP mice and the well-established increase in osteoid volume in HYP mice. These observations suggest that with addition of Klotho loss of function, the overabundant osteoid typically produced in HYP mice (but fails to mineralize) is produced and mineralized in the double knockout, resulting in markedly enhanced trabecular bone density.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952276      PMCID: PMC2817612          DOI: 10.1210/en.2009-0564

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  28 in total

Review 1.  PHEX, FGF23, DMP1 and beyond.

Authors:  Tim M Strom; Harald Jüppner
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

2.  Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.

Authors:  Toru Yoshida; Toshihiko Fujimori; Yo-Ichi Nabeshima
Journal:  Endocrinology       Date:  2002-02       Impact factor: 4.736

Review 3.  Tumor-induced osteomalacia and the regulation of phosphate homeostasis.

Authors:  R Kumar
Journal:  Bone       Date:  2000-09       Impact factor: 4.398

4.  Pathogenic role of Fgf23 in Hyp mice.

Authors:  Shiguang Liu; Jianping Zhou; Wen Tang; Xi Jiang; David W Rowe; L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-01-31       Impact factor: 4.310

5.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

Review 6.  The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis.

Authors:  Mohammed S Razzaque; Beate Lanske
Journal:  J Endocrinol       Date:  2007-07       Impact factor: 4.286

7.  The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.

Authors:  Xiu-Ying Bai; Dengshun Miao; David Goltzman; Andrew C Karaplis
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

8.  Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.

Authors:  Farzana Perwad; Martin Y H Zhang; Harriet S Tenenhouse; Anthony A Portale
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-15

9.  A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism.

Authors:  Catherine A Brownstein; Felix Adler; Carol Nelson-Williams; Junko Iijima; Peining Li; Akihiro Imura; Yo-Ichi Nabeshima; Miguel Reyes-Mugica; Thomas O Carpenter; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  FGF23, hypophosphatemia, and rickets: has phosphatonin been found?

Authors:  G J Strewler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

View more
  17 in total

1.  1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.

Authors:  Eva S Liu; Janaina S Martins; Adalbert Raimann; Byongsoo Timothy Chae; Daniel J Brooks; Vanda Jorgetti; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2016-02-02       Impact factor: 6.741

2.  Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.

Authors:  Hua Li; Aline Martin; Valentin David; L Darryl Quarles
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-07       Impact factor: 4.310

Review 3.  Molecular basis of Klotho: from gene to function in aging.

Authors:  Yuechi Xu; Zhongjie Sun
Journal:  Endocr Rev       Date:  2015-02-19       Impact factor: 19.871

4.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

5.  Na+/H+ exchanger regulatory factor 1 (NHERF1) directly regulates osteogenesis.

Authors:  Li Liu; Veronica Alonso; Lida Guo; Irina Tourkova; Sarah E Henderson; Alejandro J Almarza; Peter A Friedman; Harry C Blair
Journal:  J Biol Chem       Date:  2012-10-29       Impact factor: 5.157

6.  Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia.

Authors:  Erica L Clinkenbeard; Taryn A Cass; Pu Ni; Julia M Hum; Teresita Bellido; Matthew R Allen; Kenneth E White
Journal:  J Bone Miner Res       Date:  2016-03-04       Impact factor: 6.741

7.  Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.

Authors:  Martin Y H Zhang; Daniel Ranch; Renata C Pereira; Harvey J Armbrecht; Anthony A Portale; Farzana Perwad
Journal:  Endocrinology       Date:  2012-02-14       Impact factor: 4.736

8.  Protective roles of DMP1 in high phosphate homeostasis.

Authors:  Afsaneh Rangiani; Zhengguo Cao; Yao Sun; Yongbo Lu; Tian Gao; Baozhi Yuan; Anika Rodgers; Chunlin Qin; Makoto Kuro-O; Jian Q Feng
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  New mouse models for metabolic bone diseases generated by genome-wide ENU mutagenesis.

Authors:  Sibylle Sabrautzki; Isabel Rubio-Aliaga; Wolfgang Hans; Helmut Fuchs; Birgit Rathkolb; Julia Calzada-Wack; Christian M Cohrs; Matthias Klaften; Hartwig Seedorf; Sebastian Eck; Ana Benet-Pagès; Jack Favor; Irene Esposito; Tim M Strom; Eckhard Wolf; Bettina Lorenz-Depiereux; Martin Hrabě de Angelis
Journal:  Mamm Genome       Date:  2012-04-21       Impact factor: 2.957

10.  Dentin matrix protein 1 and phosphate homeostasis are critical for postnatal pulp, dentin and enamel formation.

Authors:  Afsaneh Rangiani; Zheng-Guo Cao; Ying Liu; Anika Voisey Rodgers; Yong Jiang; Chun-Lin Qin; Jian-Quan Feng
Journal:  Int J Oral Sci       Date:  2012-12-21       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.